This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Coty Inc., along with its subsidiaries, manufactures, markets, and distributes beauty products worldwide. The company sells its products through retailers, including hypermarkets, supermarkets, independent and chain drug stores and pharmacies, upscale perfumeries, upscale and mid-tier department stores, nail salons, specialty retailers, duty-free shops and traditional food, and drug and mass retailers. It also markets products under the Astor, Coty, Joop!, Jovan, Manhattan, and N.Y.C. New York Color brands.
COTY Set to Report Q2 Earnings: Factors to Keep in Mind
by Zacks Equity Research
COTY's second-quarter performance is likely to reflect gains across the Prestige and Consumer Beauty businesses. However, the rising cost of sales is a concern.
Unveiling Coty (COTY) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Coty (COTY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Coty (COTY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
These 2 Consumer Staples Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Coty (COTY) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Coty (COTY) closed at $12.24, indicating a +1.32% shift from the previous trading day.
Coty (COTY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Coty (COTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coty (COTY) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Coty (COTY) closed the most recent trading day at $12.16, moving +1.08% from the previous trading session.
Colgate (CL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Colgate's (CL) fourth-quarter 2023 performance is likely to have gained from solid consumer demand and efforts related to innovation, premiumization and digital transformation.
Coty (COTY) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Coty (COTY) stood at $12.24, denoting a -0.08% change from the preceding trading day.
COTY Placed Well for 2024 on Solid Beauty Trends, Strategies
by Zacks Equity Research
COTY looks well-positioned to make the most of the growing beauty market with its six strategic pillars.
Trends Redefining Beauty: What to Expect in 2024
by Ansuiya Mohta
Inter Parfums (IPAR), COTY, European Wax Center (EWCZ) and Olaplex (OLPX) are well-positioned to continue their growth story in 2024, backed by solid brand images and innovation efforts.
COTY Gains From Solid Beauty Product Business Amid Headwinds
by Zacks Equity Research
COTY gains from strength across its businesses, strategic priorities and cost optimization programs. However, it has been grappling with rising operating costs and expenses.
Coty (COTY) Up 15.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Coty (COTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights Coty, Inter Parfums, e.l.f. Beauty and European Wax Center
by Zacks Equity Research
Coty, Inter Parfums, e.l.f. Beauty and European Wax Center have been highlighted in this Industry Outlook article.
4 Cosmetics Stocks Worth Watching Amid Industry Headwinds
by Ansuiya Mohta
The Zacks Cosmetics industry is facing rising costs and supply-chain-related issues. Focus on digital business and innovations is aiding Coty, e.l.f. Beauty (ELF), Inter Parfums (IPAR) and European Wax Center (EWCZ).
COTY Benefits From its Business Strength, Headwinds Persist
by Zacks Equity Research
COTY benefits from solid momentum in its businesses and cost optimization programs. However, it has been witnessing rising operating costs and expenses.
COTY Declares Share Repurchase Authorization Worth $600M
by Zacks Equity Research
COTY approves a share repurchase program worth $600 million, bringing the total share repurchase authority close to a substantial $1 billion.
COTY Raises FY24 Revenue Outlook Despite Q1 Earnings Miss
by Zacks Equity Research
COTY's first-quarter fiscal 2024 results reflect improved sales on gains from the Prestige & Consumer Beauty business. However, earnings decline year over year.
Coty (COTY) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Coty (COTY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
COTY Set to Report Q1 Earnings: What Awaits the Stock?
by Zacks Equity Research
COTY's first-quarter results are likely to reflect gains across the Prestige and Consumer Beauty businesses. A focus on core priorities has been working well for Coty.
Pricing Aids Clorox's (CLX) Q1 Earnings Amid Cyberattack Woes
by Zacks Equity Research
Clorox's (CLX) Q1 results reflect the impacts of lower volume due to the recent cyberattack. However, results are largely offset by its pricing actions and cost-saving initiatives.
Wall Street's Insights Into Key Metrics Ahead of Coty (COTY) Q1 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Coty (COTY) for the quarter ended September 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Nu Skin (NUS) Misses Q3 Earnings Estimates, Lowers Guidance
by Zacks Equity Research
Nu Skin (NUS) faces challenging y/y comparisons and macroeconomic hurdles in Q3, leading to a downward revision in its revenue and EPS projections for 2023.
Estee Lauder (EL) Lowers FY24 View Despite Q1 Earnings Beat
by Zacks Equity Research
Estee Lauder's (EL) first-quarter fiscal 2024 results reflect lower net sales and earnings. Management lowered the fiscal 2024 view on incremental external headwinds.
Coty (COTY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Coty (COTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.